Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study)

被引：0
|
作者：
Nuria Romero-Laorden
Rebeca Lozano
Anuradha Jayaram
Fernando López-Campos
Maria I. Saez
Alvaro Montesa
Ana Gutierrez-Pecharoman
Rosa Villatoro
Bernardo Herrera
Raquel Correa
Adriana Rosero
María I. Pacheco
Teresa Garcés
Ylenia Cendón
Ma Paz Nombela
Floortje Van de Poll
Gala Grau
Leticia Rivera
Pedro P. López
Juan-Jesús Cruz
David Lorente
Gerhardt Attard
Elena Castro
David Olmos
机构：
[1] Spanish National Cancer Research Centre (CNIO),Prostate Cancer Clinical Research Unit
[2] Hospital Universitario de La Princesa,Medical Oncology Department
[3] Hospital Universitario de Salamanca,Medical Oncology Department
[4] Institute of Biomedical Research in Málaga (IBIMA),CNIO
[5] The Institute of Cancer Research,IBIMA Genitourinary Cancer Research Unit
[6] The Royal Marsden NHS Foundation Trust,Division of Molecular Pathology, Centre for Evolution and Cancer
[7] Hospital Universitario Ramón y Cajal,Academic Urology
[8] Hospitales Universitarios Virgen de la Victoria y Regional de Málaga,Radiation Oncology Department
[9] Hospital Universitario de Móstoles,Medical Oncology Department
[10] Hospital Costa del Sol,Pathology Department
[11] Hospital Universitario Virgen de la Victoria,Medical Oncology Department
[12] Hospital Universitario Virgen de la Victoria,Urology Department
[13] Hospital Universitario Fundación Alcorcón,Radiation Oncology Department
[14] Universidad Autónoma de Madrid,Oncology Department
[15] Hospital Universitario La Fe,School of Medicine
[16] Hospital Universitario Quirón,Medical Oncology Department
来源：
British Journal of Cancer | 2018年 / 119卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1052 / 1059
页数：7
相关论文
共 50 条
  • [1] Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study)
    Romero-Laorden, Nuria
    Lozano, Rebeca
    Jayaram, Anuradha
    Lopez-Campos, Fernando
    Saez, Maria, I
    Montesa, Alvaro
    Gutierrez-Pecharoman, Ana
    Villatoro, Rosa
    Herrera, Bernardo
    Correa, Raquel
    Rosero, Adriana
    Pacheco, Maria, I
    Garces, Teresa
    Cendon, Ylenia
    Paz Nombela, Ma
    Van de Poll, Floortje
    Grau, Gala
    Rivera, Leticia
    Lopez, Pedro P.
    Cruz, Juan-Jesus
    Lorente, David
    Attard, Gerhardt
    Castro, Elena
    Olmos, David
    BRITISH JOURNAL OF CANCER, 2018, 119 (09) : 1052 - 1059
  • [2] Phase II study of prednisone-dexamethasone switch in metastatic castration resistant prostate cancer (mCRPC) patients treated with abiraterone and prednisone (AA plus P)
    Lozano Mejorada, R.
    Romero Laorden, N.
    Jayaram, A.
    Lopez, F.
    Saez, M. I.
    Villatoro, R.
    Montesa, A.
    Moreno, I.
    Ruiz Vico, M.
    Garcia Ferron, M.
    Rogado, J.
    Cendon Florez, Y.
    Nombela Blanco, P.
    Rivera, L.
    Grau, G.
    Cruz Hernandez, J. J.
    Lorente Estelles, D.
    Attard, G.
    Castro Marcos, E.
    Olmos Hidalgo, D.
    ANNALS OF ONCOLOGY, 2017, 28
  • [3] Switch from abiraterone plus prednisone to abiraterone plus dexamethasone after PSA progression under abiraterone plus prednisone in asymptomatic metastatic castration-resistant prostate cancer (mCRPC) patients
    Fenioux, C.
    Louvet, C.
    Prapotnich, D.
    Ropert, S.
    Barret, E.
    Sanchez-Salas, R.
    Mombet, A.
    Cathala, N.
    Poullennec, B.
    Joulia, M-L.
    Ung, M.
    Cathelineau, X.
    Bennamoun, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [4] Corticosteroid switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone
    Yang, Zhenyu
    Ni, Yuchao
    Zhao, Diwei
    Zhang, Yijun
    Wang, Jun
    Jiang, Lijuan
    Chen, Dong
    Wu, Zhiming
    Wang, Yanjun
    He, Liru
    Shi, Yanxia
    Zhou, Fangjian
    Zeng, Hao
    Li, Yonghong
    BMC CANCER, 2021, 21 (01)
  • [5] Corticosteroid switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone
    Zhenyu Yang
    Yuchao Ni
    Diwei Zhao
    Yijun Zhang
    Jun Wang
    Lijuan Jiang
    Dong Chen
    Zhiming Wu
    Yanjun Wang
    Liru He
    Yanxia Shi
    Fangjian Zhou
    Hao Zeng
    Yonghong Li
    BMC Cancer, 21
  • [6] Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer
    Fenioux, Charlotte
    Louvet, Christophe
    Charton, Emilie
    Rozet, Francois
    Ropert, Stanislas
    Prapotnich, Dominique
    Barret, Eric
    Sanchez-Salas, Rafael
    Mombet, Annick
    Cathala, Nathalie
    Joulia, Marie-Liesse
    Molitor, Jean-Luc
    Henriques, Julie
    Bonnetain, Franck
    Cathelineau, Xavier
    Bennamoun, Mostefa
    BJU INTERNATIONAL, 2019, 123 (02) : 300 - 306
  • [7] A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Einstein, David Johnson
    Choudhury, Atish Dipankar
    Saylor, Philip James
    Werner, Lillian
    Erlander, Mark G.
    Ridinger, Maya
    Bubley, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [8] A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Einstein, David Johnson
    Choudhury, Atish Dipankar
    Saylor, Philip James
    Patterson, Jesse Christopher
    Croucher, Peter
    Ridinger, Maya
    Erlander, Mark G.
    Yaffe, Michael B.
    Bubley, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [9] Steroid switch after progression on abiraterone plus prednisone in patients with metastatic castration-resistant prostate cancer: A systematic review
    Xiong, Xingyu
    Qiu, Shi
    Yi, Xianyanling
    Xu, Hang
    Liao, Dazhou
    Lei, Haoran
    Bai, Shengjiang
    Peng, Ge
    Ai, Jianzhong
    Yang, Lu
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2021, 39 (11) : 754 - 763
  • [10] A phase 2 study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Einstein, David Johnson
    Choudhury, Atish Dipankar
    Saylor, Philip James
    Patterson, Jesse Christopher
    Croucher, Peter
    Ridinger, Maya
    Erlander, Mark G.
    Yaffe, Michael B.
    Bubley, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
12345